Navigation Links
Fontus Pharmaceuticals Acquires Nephrology and Endocrinology Drug from Roche Laboratories Inc.
Date:6/16/2008

Launches Nephrology and Endocrinology Product Line

PARSIPPANY, N.J., June 16 /PRNewswire/ -- Fontus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on nephrology and endocrinology, announced today that it has acquired ROCALTROL(R) (calcitriol) from Roche Laboratories Inc. ROCALTROL is a vitamin D analog prescribed by nephrologists for the management of hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (CRF) and by endocrinologists for the management of hypocalcemia in patients with post-surgical hypoparathyroidism, idiopathic hypoparathyroidism and pseudohypoparathyroidism.

About ROCALTROL(R) (calcitriol)

ROCALTROL, available as capsules and as an oral solution, is the most potent metabolite of vitamin D available and is active in regulating the absorption of calcium from the gastrointestinal tract and its utilization in the body. The calcitriol in ROCALTROL is believed to be the active hormone which exerts vitamin D activity in the body. ROCALTROL improves calcium absorption in patients who have severe vitamin D deficiencies commonly associated with CRF, chronic kidney disease (CKD), end-stage renal disease (ESRD) or primary hypothyroidism.

ROCALTROL therapy should always be started at the lowest possible dose and should not be increased without careful monitoring of serum calcium. In order to avoid hypercalcemia and related conditions, the optimal daily dose of ROCALTROL must be carefully determined for each patient. The safety and effectiveness of ROCALTROL in pediatric predialysis patients is based on evidence from adequate and well controlled studies of ROCALTROL in adults with predialysis chronic renal failure and additional supportive data from non-placebo controlled studies in pediatric patients. Specific doses of ROCALTROL are recommended for pediatric predialysis patients. These and other precautions and warnings may be found in the package insert for ROCALTROL.

About Fontus Pharmaceuticals

Fontus Pharmaceuticals, Inc. ("Fontus") is a specialty pharmaceutical company distinguished by its strategy to acquire and market FDA-approved products used in the fields of nephrology and endocrinology. Fontus focuses on mature products with widely accepted clinical value and brand loyalty. Fontus re-invigorates promotion and in some cases reformulates products to optimize clinical benefit. Fontus is the second new specialty pharmaceutical company to be formed with an investment from the private equity fund, Konanda Pharma Fund I, L.P. For more information, please visit http://www.fontuspharma.com.

About Konanda Pharma Fund I, L.P.

Konanda Pharma Fund I, L.P. is a private equity fund that founds and invests in portfolio companies that acquire mature prescription drug brands that offer important therapeutic benefits. For more information, please visit http://www.konanda.com.


'/>"/>
SOURCE Fontus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Celator(R) Pharmaceuticals to Present at 2008 BIO International Convention
2. Scimitar Equity, LLC Initiates Coverage Review of VioQuest Pharmaceuticals, Inc.
3. GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections
4. Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention
5. Jazz Pharmaceuticals Files Form S-3 Registration Statements
6. Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference
7. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
8. The Leukemia & Lymphoma Society and Provid Pharmaceuticals Announce Collaboration on Treatment for Acute Myelogenous Leukemia
9. Diffusion Pharmaceuticals Announces Addition of Mark T. Giles to its Board of Directors
10. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
11. Amira Pharmaceuticals Hires Industry Veteran for CFO Position
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 2016 Sinovac Biotech Ltd. ("Sinovac" or the ... biopharmaceutical products in China , today ... directors received on February 4, 2016 a preliminary non-binding ... comprised of PKU V-Ming ( Shanghai ) ... Qianhai Development ( Shenzhen ) Fund Management ...
(Date:2/3/2016)... 3, 2016  Discovery Laboratories, Inc. (NASDAQ: ... aerosolized KL4 surfactant therapies for respiratory diseases, today ... an inducement award as a component of employment ... appointed President and Chief Executive Officer.  The award ... February 1, 2016 and granted as an inducement ...
(Date:2/3/2016)... ... February 03, 2016 , ... Aerocom, a world-leading supplier ... the North American healthcare market. , Aerocom Healthcare, LLC will be based in ... will provide new pneumatic tube systems or expand existing systems within the U.S. ...
(Date:2/3/2016)... 2016  Today, Symphony Technology Group (STG) announced the ... leading provider of primary research and analytics-based insight for ... , a global information and technology services company serving ... will be integrated into IMS Health to form a ... capabilities. ...
Breaking Biology Technology:
(Date:2/3/2016)... 2016 --> --> Fourth ... (105.0), up 1,187% compared with fourth quarter of 2014. Gross ... M (loss: 30.0). Earnings per share increased to SEK 6.39 ... M (neg: 74.7). , --> ... SEK 2,900.5 M (233.6), up 1,142% compared with 2014. Gross ...
(Date:2/3/2016)... , Feb. 3, 2016 ... addition of the "Emotion Detection and ... Learning, and Others), Software Tools (Facial Expression, ... End Users,and Regions - Global forecast to ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced ...
(Date:2/2/2016)... YORK , Feb. 2, 2016 ... of that Rising Market Are you interested ... analysis forecasts revenues for checkpoint inhibitors. Visiongain,s report ... market, submarket, product and national level. Avoid ... discover what progress, opportunities and revenues those emerging ...
Breaking Biology News(10 mins):